What is Giant Biogene Holding Co Enterprise Value?
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Giant Biogene Holding Co's Enterprise Value is HK$44,933 Mil.
Giant Biogene Holding Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1,909 Mil. Therefore, Giant Biogene Holding Co's EV-to-EBIT ratio for today is 23.54.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Giant Biogene Holding Co's Enterprise Value
For the Household & Personal Products subindustry, Giant Biogene Holding Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Giant Biogene Holding Co's Enterprise Value Distribution in the Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Giant Biogene Holding Co's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Giant Biogene Holding Co's Enterprise Value falls into.
Giant Biogene Holding Co Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Giant Biogene Holding Co's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Giant Biogene Holding Co (HKSE:02367) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Giant Biogene Holding Co's EV-to-EBIT for today is
Giant Biogene Holding Co's current Enterprise Value is HK$44,933 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Giant Biogene Holding Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1,909 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Giant Biogene Holding Co's EV-to-EBITDA for today is:
Giant Biogene Holding Co's current Enterprise Value is HK$44,933 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Giant Biogene Holding Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1,946 Mil.
Giant Biogene Holding Co's current Enterprise Value is HK$44,933 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Giant Biogene Holding Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$3,855 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Giant Biogene Holding Co Enterprise Value Related Terms
Thank you for viewing the detailed overview of Giant Biogene Holding Co's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Giant Biogene Holding Co (HKSE:02367) Business Description
Giant Biogene Holding Co Ltd design, develop and manufacture professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenosides technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty and health properties such as skin repair, anti-aging, whitening, moisturizing and immunity improvement with a broad range of applications in the beauty and health sectors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02367 has been successfully added to your